Abera Bioscience carries out directed issue of units to finance clinical Phase I study of pneumococcal vaccine candidate Ab-01.12
Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that the Board of Directors has resolved,